First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
Status: NOT_YET_RECRUITING
Study type: INTERVENTIONAL
Conditions: Advanced Cancer|Breast Cancer
Interventions: DRUG: OKI-219|DRUG: Fulvestrant|DRUG: Trastuzumab
Sponsor: OnKure, Inc.